Osteosarcoma is the most common primary malignant bone tumor among adolescents worldwide with high mortality rate. Glycogen synthase kinase 3β (GSK3β) is a serine/threonine kinase and is considered as a validated target in osteosarcoma therapy. Therefore, the study of GSK3β inhibitors is one of the most popular fields in anti-osteosarcoma drug development. Here, the tools of bioinformatics were used to screen novel effective inhibitors of GSK3β from ZINC Drug Database. The molecular docking, molecular dynamic simulations, MM/GBSA, and energy decomposition analysis were performed to identify the inhibitors. Finally, ZINC08383479 and ZINC08441251 were selected as potential GSK3β inhibitors. These two inhibitors were evaluated by GSK3β kinase inhibition assay in vitro. The inhibition of cell proliferation was tested in osteosarcoma cell lines U2OS and MG63 in vitro. The result showed that ZINC08383479 and ZINC08441251 had high inhibition activity against GSK3β. We found that CHIR99021 (a known GSK3β inhibitor), ZINC08383479, and ZINC08441251 had significant inhibition activity in U2OS cells and MG63 cells. These findings may provide new ideas for the design of more potent GSK3β inhibitors and therapeutic targets for osteosarcoma.
Introduction
Osteosarcoma is the most common primary malignant bone tumor in adolescents and young adults with a high tendency of local invasion and distant metastasis [1, 2] . There is no obvious symptom at the early stage, which can give rise to many deaths owing to the rapid proliferation and metastasis of osteosarcoma cells [3] . Recurrent disease still occurs in about 30%-40% of patients [4] . Despite advancements in multimodality treatments, the current therapies often result in chemoresistance [5] . Thus, identifying new targets and elucidating mechanisms are highly needed for the treatment of osteosarcoma [6, 7] .
Glycogen synthase kinase 3β (GSK3β) is a protein kinase that phosphorylates and inactivates glycogen synthase, a key enzyme in the glycogen metabolism [8] . GSK3β is a multi-substrate target protein kinase, and plays a regulatory role in protein degradation, cell differentiation, metabolism, apoptosis, and inflammation [9, 10] . Dysregulation of GSK3β can contribute to the development of many human diseases such as Alzheimer's disease, diabetes, cardiovascular disease, and some neurodegenerative diseases [11] . Recently, increasing evidence suggests that GSK3β can serve as a potential therapeutic target, because it is aberrantly activated in various types of cancers [12] . GSK3β serves as both tumor suppressor and tumor promoter, depending on different cell types and cellular context [11] . For example, GSK3β is recognized as a tumorigenesis in human oral, colon, ovarian, and mixed lineage leukemia cancer, while it is recognized as a tumor suppressor in gastric and non-melanoma cancers [13, 14] . GSK3β is a crucial member in various signaling pathways, including NF-κB [15] , insulin [16] , Wnt/β-catenin [17] , Hedgehog [18] , and Notch [19] pathways. However, some studies showed that GSK3β is involved in multiple molecular pathways which are used by various cancer types to evade chemotherapy, radiotherapy, and targeted therapies [12] . Therefore, targeting GSK3β may be a promising novel cancer therapeutic strategy.
Currently, several studies have shown that the expression of GSK3β is increased in osteosarcoma compared with normal cells and tissues [20] . Recent studies have shown that downregulated GSK3β might actually attenuate the viability of tumor cells and induce apoptosis in human osteosarcoma [21] . Therefore, we select GSK3β as a target to treat osteosarcoma.
Many inhibitors of GSK3β have been identified, such as compounds isolated from natural sources, cations, synthetic small-molecule ATP-competitive inhibitors, non-ATP-competitive inhibitors, and substrate-competitive inhibitors [22] . Among these known inhibitors, AR-A014418, SB-216763, and cation lithium have been used in osteosarcoma studies. AR-A014418 and SB-216763 are ATP-competitive inhibitors of GSK3β from organic synthesis programs. However, there are issues involving selectivity of inhibitors in relation to other kinases with similar structure as well as its isoforms-GSK3α, though a plenty of inhibitors of GSK3β have been identified [23] . Some GSK3β inhibitor drugs have been eliminated from the market due to their poor selectivity [24] . Hence, there is an urgent need to search for novel GSK3β inhibitors with potent selectivity.
In this study, we utilized the high-through put screening from Zinc Drug Database to find novel potential GSK3β inhibitors. We selected several small molecules with lower GB/SA Hawkins scores as the candidates compared with the reference ligand 7-hydroxy-1H-benzoimidazole. To identify the best inhibitors among the candidates, we performed the molecular dynamic (MD) simulations, MM/GBSA, and energy decomposition analysis. Finally, two small molecules were selected as our candidates and evaluated by GSK3β kinase inhibition assay and the cell proliferation inhibition assay using two cell lines U2OS and MG63 cell lines in vitro. Our findings may provide some useful information for the search of novel inhibitors of GSK3β that can be used in osteosarcoma treatment in the future.
Materials and Methods

Structure preparation
The crystal structure of GSK3β (PDB entry: 2O5K) [24] in complex with the substrate-like inhibitor 7-hydroxy-1H-benzoimidazole was downloaded from the Protein Data Bank (PDB) (http://www.pdb. org/pdb/home/home.do).
We collected 32791 candidate molecules which were commercially available from Specs subset in the ZINC database (http://zinc. docking.org/catalogs/specsnp). The 3D format structures of these small molecules were prepared for docking [25] .
Molecular docking
The UCSF chimera (version 1.8.1) was used to prepare the ligand and receptor files. The preparation process included removing hydrogen atoms, adding standard charge and the elimination of solvent molecules. To improve accuracy, we selected the 2.0 Å root mean square deviations (RMSDs) of the primitive ligand. Then screening a series of candidates performed by UCSF DOCK (version 6.5) [26] . Then, the docking process was carried out according to the DOCK6 user manual (http://dock.compbio.ucsf.edu/DOCK_6/dock6_manual.htm).
To explore the docked poses, Hawkins GB/SA score [27] was employed to screen potential inhibitors.
Model validation
The receiver operating characteristic (ROC) curve was analyzed to assess the reliability of virtual screening by applying the method of docking simulation [28] . The database used to simulate the docking test is composed of 31 positive ligands (i.e. existing GSK3β inhibitors) and 565 decoys. The structures of 31 GSK3β inhibitors that we collected from papers and literature were downloaded from ZINC Database. Then, Decoy Finder software [29] was utilized to find decoys that were presumed to be inactive against GSK3β. Finally, the 31 positive ligands and 565 negative decoys were scored and ranked by Hawkins GB/SA algorithm. SPSS (version 22) was used to draw the ROC to calculate the area under the ROC curve (AUC).
MD simulation GROMACS 4.5.5 program [30] was used to perform the MD simulations. We performed the program pdb2gmx with the AMBER99SB force field [31] and the TIP3P water model [32] to generate files of receptor protein topology. Under periodic boundary conditions (PBC) along with a dodecahedral periodic box, the simulation was executed with the minimal distance of 0.1 nm to the margin of the box. Adding the simple point charge (SPC) water molecules to the box made it solvate. Then, Na + and Cl − were added to make system neutral which the final salt concentration was 0.15 M. Utilizing the steepest descent minimization algorithm for all atoms made the system energy minimize and the maximum force limited to 1000 kcal/mol/nm. Then the system reached equilibrium with the 100 ps NVT (constant number of particles, volume, and temperature) and 100 ps NPT (constant number of particles, pressure, and temperature). Finally, we performed a 25 ns MD simulation with a 2 fs timestep under the condition of 300 k and 1 atm for GSK3β-ligand complexes. During the process of simulation, we applied LINCS algorithm [33] by bond lengths, and particle mesh Ewald (PME) method [34] for long-range electrostatics. The trajectory and energy information of various GSK3β-ligand complexes were analyzed via GROMACS package (version 4.5.5), which included the analysis of RMSD and root mean square fluctuation (RMSF).
Binding mode comparison
The LIGPLOT + software (version 1.4.5) [28] was used to analyze the hydrogen bonds and hydrophobic interactions between GSK3β and small molecules. Using the LIGPLOT algorithm [35] , we converted the 3D protein-ligand complexes generated during MD simulations to 2D diagrams.
MM/GBSA binding-energy calculations and energy decomposition analysis
The MM/GBSA [36] was widely used to calculate the binding free energy (ΔG bind ) of biomolecular complexes by using g_mmpbsa tutorial [37] . In this approach, ΔG bind calculation formula [38] is
The gas-phase interaction energy (E MM ) consisted of the bonded interactions (E bonded ), van der Waals (E vdW ) and electrostatic interaction (E ele ) energies between receptor and ligand, and the solvation free energy (G sol ) was composed of the polar energy (G polar ) and nonpolar energy (G nonpolar ). And the conformations of protein and ligand were identified as a constant, so ΔE bonded was usually taken as zero. The entropic contribution (−TΔS) was not considered here because of its expensive computational cost and low prediction.
Therefore, the binding free energy involved Van der Waals contribution (E vdW ), electrostatic contribution (E ele ), the polar part of desolvation (G polar ) and nonpolar contributions (G nonpolar ). Thus
Enzymatic activity assay and cell proliferation inhibition assay in vitro
The selected inhibitors were tested for GSK3β kinase inhibition abilities by Human GSK3β kinase ELISA kit (Mlbio, Shanghai, China). Experiments were performed according to the instructions of the kit. Firstly, 50 μl of compound solution was added to the 100 μl antibody labeled by horseradish peroxidase (HRP). Then, the mixture solution on the plate was incubated for 1 h at 37°C. Next, the A and B substrate peptides were added to the well, and the plate was incubated for 15 min at 37°C in the dark. To terminate the reaction, 50 μl of stop reagent was added. The Infinite M100 Pro multi-label reader was used to measure the activity. Osteosarcoma cell lines U2OS and MG63 were obtained from ATCC (Manassas, USA). U2OS cells and MG63 cells were cultured in Dulbecco's modified Eagle's medium (GIBCO, Gaithersburg, USA) supplemented with 10% fetal bovine serum (GIBCO) at 37°C with 5% CO 2 . U2OS and MG63 cells were seeded in 96-well plates at a density of 2 × 10 4 /ml per well. They were treated with different concentrations of CHIR99021 (3-33 nM) and selected compounds (0.5-4 nM) for 48 h, and then cell viability was measured by CCK-8 assay (Biosharp, Guangzhou China). Graph Pad Prism 5.0 was applied to calculate the rate of cell proliferation inhibition and the IC 50 values.
Results
Docking accuracy
To assess the docking accuracy, we docked the ligands (including 31 positive ligands and 565 decoys) to GSK3β. ROC curve and AUC of the simulated docking test were shown in Fig. 1 . The value of AUC was 0.791, which was greater than 0.7, indicating that the accuracy of docking was efficient and reliable.
Screening for potential GSK3β inhibitors by molecular docking
In order to screen for potential GSK3β inhibitors, we docked 31 known inhibitors and all molecules from Specs chemistry database into the active sites of GSK3β by the DOCK6 program. Then the binding affinity of GSK3β-ligand complexes was scored and ranked by Hawkins GB/SA algorithm. The top100 Hawkins GB/SA scores were listed in Supplementary Table S1 and the distribution of Hawkins GB/SA score was shown in Supplementary Fig. S1 . The top10 Hawkins GB/SA scores are shown in ). They showed higher binding affinity than known inhibitors of GSK3β, so these molecules were selected for further MD simulations analysis.
MD simulation
The 25 ns MD simulations between GSK3β and its candidates were performed to assess the dynamic interactions along with the reference of 7-hydroxy-1H-benzoimidazole. We could know the interactions and the combined conformation between receptor and ligands via the trajectories of MD simulations. The analysis of RMSD and Per-residue RMSF elaborated the structural stability and residue flexibility of complexes.
The backbone RMSD values of GSK3β were calculated to examine the dynamic stability of the receptor-ligand complexes. As shown in Low value of RMSF means that the system is stable and the residues of this region may be involved in the binding interactions of receptor-ligand. Figure 2B shows the backbone RMSF of the 7-hydroxy-1H-benzoimidazole and the four small molecules with the receptor. These five systems shared similar fluctuations in most regions. Meanwhile, we considered the critical residues in ATP-binding site, such as Lys85, Asp133, Val135, Thr138, Lys183, Gln185, and Asp200 [22] , and the binding pocket of the predicted phosphate group including Arg96, Arg180, and Lys205 [39] . Compared with GSK3β-7-hydroxy-1H-benzoimidazole system, ZINC08441251-and ZINC08387149-GSK3β complexes showed lower RMSF value at Arg96, which exhibited lower flexibility. The positions of these critical residues of the four ligand-GSK3β systems were similar to the GSK3β-7-hydroxy-1H-benzoimidazole complex. Therefore, ZINC08441251 and ZINC08383479 were better candidates.
Binding mode comparison between GSK3β and its different ligands
The binding modes of GSK3β-7-hydroxy-1H-benzoimidazole complex and four GSK3β-molecule complexes were generated by LIGPLOT program. It determined the interaction mechanism between GSK3β and molecules and the mutual effect of key residues during the steady time of MD simulations. The structure of GSK3β kinase domain comprises a small N-terminal domain and a larger C-terminal domain, which is a typical structure of protein kinase [40] . The binding pocket of small molecules was located in catalytic structural domain between C-terminal and N-terminal. The four potential inhibitors located in the ATP-binding pocket formed hydrogen bond with the important residues of GSK3β as well as the reference. For GSK3β-7-hydroxy-1H-benzoimidazole complex (Fig. 3A) , Val135, Arg220, and Arg141 participated in the formation of four hydrogen bonds with distance 3.14 Å, 3.34 Å, 2.72 Å, and 3.26 Å respectively. In addition, as shown in Fig. 3A , residues Ile62, Lys85, Asp133, Tyr134, Pro136, Ala83, Asp200, Gln185, Val70, Tyr140, and Asn186 were involved in the formation of hydrophobic interactions. ZINC08383479 (Fig. 3B) formed one hydrogen bond (3.13 Å) with Lys183; and ZINC08441251 ( Fig. 3C ) formed one hydrogen bond (2.86 Å) with Lys183 (2.86 Å). Meanwhile, six hydrogen bonds (2.99 Å, 2.97 Å, 2.89 Å, 2.79 Å, 2.93 Å, and 2.90 Å) were formed for GSK3β-ZINC08387149 complex with Arg141, Lys85, Asp200, Asn64, Phe67, and Ser66 respectively (Fig. 3D) . For the GSK3β-ZINC22790008 system (Fig. 3E) , Cys218, Asn186, Asp200, and Lys183 participated in the formation of hydrogen with 2.86 Å, 2.87 Å, 2.80 Å, and 3.21 Å respectively. The binding mode of ZINC08383479-and ZINC08441251-GSK3β complexes were similar to the GSK3β-7-hydroxy-1H-benzoimidazole system because of the same residues involved in the hydrophobic interaction, including residues Ile62, Ala83, Gln85, and Asp200. This result suggested that these residues played a key role in the interaction mechanism of GSK3β-molecules.
Binding free energy of GSK3β-ligand complexes
For more information about interactions between four candidates, 7-hydroxy-1H-benzoimidazole and GSK3β, we employed the MM/GBSA method to calculate the binding free energy. The binding free energy and energy components of each system complex are listed in Table 2 . The lower binding free energy indicates that the complex is more stable. As shown in Table 2 , for the GSK3β-7-hydroxy-1H-benzoimidazole system, the binding free energy was −41.92 kcal mol . For ZINC08383479 and ZINC08441251, the binding free energies were −38.12 kcal mol −1 and −20.34 kcal mol −1 respectively, suggesting that they exhibited higher binding affinity to GSK3β than ZINC08387149 and ZINC22790008. Additionally, the four key elements of the binding free energies were also analyzed, including van der Waals energy (ΔE vdw ), electrostatic interaction energy (ΔE ele ), polar solvation energy (ΔG polar ), and nonpolar salvation energy (ΔG nonpolar ). As shown in Table 2 , the ΔE vdw of the GSK3β-ligand systems were almost lower than −40 kcal mol
, which was vital to the binding contribution. The ΔG polar of each system complex was significantly unfavorable to the binding with over 55 kcal mol −1 . Moreover, the ΔG nonpolar were slightly different among four complexes. For the ZINC08387149-and ZINC22790008-GSK3β systems, the ΔE ele contribution was useless to the binding energy. But for ZINC08383479 and ZINC08441251, ΔE ele contribution was important for the binding process. Compared with 7-hydroxy-1H-benzoimidazole, ZINC08383479, and ZINC08441251 were more likely to be candidates.
The results of binding free energy decomposition
ZINC08383479 and ZINC08441251 were selected for further analysis. MM/GBSA method was employed to further identify the contributions of each residue in the ligand-protein binding models. The energy contributions of all residues were shown in Fig. 4 . For the GSK3β-7-hydroxy-1H-benzoimidazole system (Fig. 4A) , it was found that residues Ile62, Gly65, Val70, Glu80, Ala83, Leu132, Tyr134, Thr138, Tyr140, Arg141, Lys183, and Leu188 played a key role in energy contribution. As shown in Fig. 4B ,C, the residues of the ZINC08383479-and ZINC08441251-GSK3β systems had similar results from energy decomposition. Residues Asp58, Gly63, Phe67, Val70, Ala83, Asp90, Glu121, Asp124, Glu125, Leu132, Arg148, Lys150, and Lys159 provided greater energy contributions, among which Asp58, Val70, Ala83, and Leu132 were the same as the GSK3β-7-hydroxy-1H-benzoimidazole system, indicating that they were key residues for ligand binding. Furthermore, most of these critical residues were hydrophobic, implying that hydrophobic interactions might be crucial for the binding of ligand. Above all, we could confirm that ZINC08383479-and ZINC08441251-GSK3β complexes had higher repetitive rate of key residues energetic contributions. ZINC08383479 and ZINC08441251 were more likely to serve as the inhibitors of GSK3β.
Enzymatic activity and cell proliferation inhibition activity in vitro ZINC08383479 and ZINC08441251 were selected to further analysis for GSK3β kinase inhibition activity and cell proliferation inhibition activity in vitro. As shown in Table 3 , the selected inhibitors showed obvious kinase inhibition activity against GSK3β. As shown in Fig. 5 , the CHIR99021 and two selected small molecules had significant inhibition activity in osteosarcoma cell lines U2OS and MG63. The concentration of inhibitors was positively correlated with the inhibition ratio. Moreover, the cell proliferation inhibition activities were in agreement with the results of kinase inhibition assay.
In particular, ZINC08383479 and ZINC08441251 showed high inhibition activity against GSK3β. As shown in Table 3 , ZINC08383479 and ZINC08441251 exhibited high activities with IC 50 value of 3.436 nM and 2.625 nM against GSK3β, respectively.
As shown in Fig. 5A , the inhibition ratio of CHIR99021 in U2OS cells was 82.4% at 0.5 μM. The inhibition ratios of the ZINC08383479 and ZINC08441251 were 85.9% and 83.3% at 4 nM, respectively (Fig. 5A) . As shown in Fig. 5B , the inhibition ratios of three inhibitors in MG63 cells were 65.8% (CHIR99021, 33 nM), 87.8% (ZINC08383479, 4 nM), and 89.8% (ZINC08441251, 4 nM). As shown in Table 3 , 
Discussion
Some previous studies showed that the inhibition of GSK3β activity by inhibitors can attenuate the survival and proliferation of tumor cells and induce apoptosis [12] , such as glioblastoma [41] , and osteosarcoma [42] . Searching for and designing of selective GSK3β inhibitors are essential due to the therapeutic benefit [22] . Therefore, we applied computer-aided drug design to screen inhibitors of GSK3β by molecular docking, MD simulation, binding model analysis, and MM/GBSA, which could make the results more reliable and more accurate. Two candidates ZINC08383479 and ZINC08441251 were selected as the inhibitors of GSK3β. And the two screened inhibitors showed significant suppression activity against GSK3β and presented outstanding cell proliferation inhibition activity against osteosarcoma cell lines U2OS and MG63. The regulation of GSK3β activity and its preference for substrates were provided via the analysis of structure. The studies of crystal structure showed a phosphate binding pocket which can bind with the phosphorylated substrate, including three residues, Arg96, Lys205, and Arg189 [39] . Specific interactions within the ATP-binding pocket include residues Asp133, Arg141, Gln185, Asp200, Arg220, and the conserved salt bridge of Lys85/Glu97 [22] . The phosphorylated Tyr216 can activate GSK3β, and residue Tyr216 plays a role in the 'gate' of the substrate-binding site [43] . In GSK3β, residues Ile62, Val70, Ala83, Val110, Leu132, Tyr134, and Leu188 could make hydrophobic interactions with inhibitors [40] . Thus, these residues aforementioned play a key role in the interaction mechanism of GSK3β-molecules. We found that ZINC08441251-and ZINC08387149-GSK3β complexes had lower RMSF value (Fig. 2B) at Arg96. The residues Ile62, Ala83, Gln85, and Asp200 were involved in the hydrophobic interaction with ZINC08383479 ( Fig. 3B) and ZINC08441251 (Fig. 3C) . Residues Asp58, Val70, Ala83, and Leu132 provided greater energy contributions (Fig. 4) . These residues were hydrophobic, implying that hydrophobic interactions might be crucial for the binding of ligand. These findings suggested that the advanced structure-based computational methods might ensure accuracy and improve inhibitor specificity. Therefore, ZINC08383479 and ZINC08441251 were chosen as GSK3β inhibitors.
CHIR99021 is a potent and highly selective aminopyrimidine GSK3β inhibitor. Because the original ligand 7-hydroxy-1H-benzoimidazole is not available, CHIR99021, a commercial inhibitor of GSK3β, is selected as the positive control in GSK3β kinase inhibition assay and cell proliferation inhibition assay. Two selected inhibitors showed obvious suppression activity against GSK3β. A previous study showed that the IC 50 of CHIR99021, AR-A014418, and SB-216763 against GSK3β are 6.7 nM, 34 nM, and 104 nM, respectively [22] . Moreover, as shown in Table 3 , the IC 50 values of ZINC08383479 and ZINC08441251 against GSK3β were 3.436 nM and 2.625 nM, respectively, suggesting that ZINC08383479 and ZINC08441251 can be the potential GSK3β inhibitors. As shown in Fig. 5 , compared with CHIR99021, ZINC08383479 and ZINC08441251 had more outstanding inhibition activity to osteosarcoma cell lines U2OS and MG63. It has been shown that the viability of osteosarcoma cells is reduced after being treated with AR-A014418 or SB-216763 [44] . The IC 50 values of AR-A014418 and SB-216763 are 16.0 μM and 14.3 μM, respectively, in MG63 cells [44] . The IC 50 of CHIR99021 was 10.64 nM in U2OS cells, and 18.56 nM in MG63 cells. While the IC 50 values of ZINC08383479 and ZINC08441251 were 2.037 nM and 2.719 nM, respectively, in U2OS cells, and 2.094 nM and 1.985 nM, respectively, in MG63 cells. These findings indicated that ZINC08383479 and ZINC08441251 had more potent capacity to suppress the proliferation in osteosarcoma.
Recently, it is suggested that GSK3β inhibition can induce the suppression of tumor cell survival and proliferation by inhibiting NF-κB transcriptional activity and restoring β-catenin osteosarcoma suppressor [21] . But the inhibition mechanism of ZINC08383479 and ZINC08441251 in U2OS cells and MG63 cells has not been explored.
In summary, ZINC08383479 and ZINC08441251 showed higher inhibition abilities against GSK3β and had obvious inhibition activity to osteosarcoma cell lines U2OS and MG63. Our findings may pave new way for the design of more potent GSK3β inhibitors and therapeutic target for the treatment of osteosarcoma.
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